<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>HER2 on CMC Seoul OBY &amp; Breast Pathology</title>
    <link>https://extraordinary-tulumba-269604.netlify.app/categories/her2/</link>
    <description>Recent content in HER2 on CMC Seoul OBY &amp; Breast Pathology</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 11 Jun 2022 00:00:00 +0000</lastBuildDate><atom:link href="https://extraordinary-tulumba-269604.netlify.app/categories/her2/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>HER2 Testing in Breast Cancer - 2018 Focused Update</title>
      <link>https://extraordinary-tulumba-269604.netlify.app/docs/breast/2022-06-11-her2-testing-in-breast-cancer-2018-focused-update/</link>
      <pubDate>Sat, 11 Jun 2022 00:00:00 +0000</pubDate>
      
      <guid>https://extraordinary-tulumba-269604.netlify.app/docs/breast/2022-06-11-her2-testing-in-breast-cancer-2018-focused-update/</guid>
      <description>HER2 Testing in Breast Cancer - 2018 Focused Updatehttps://www.cap.org/protocols-and-guidelines/cap-guidelines/current-cap-guidelines/recommendations-for-human-epidermal-growth-factor-2-testing-in-breast-cancer</description>
    </item>
    
  </channel>
</rss>
